Nisa Investment Advisors LLC Sells 7,746 Shares of Edwards Lifesciences Corporation $EW

Nisa Investment Advisors LLC cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 245,311 shares of the medical research company’s stock after selling 7,746 shares during the period. Nisa Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $19,078,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $266,000. Caxton Associates LLP bought a new stake in Edwards Lifesciences during the first quarter worth about $370,000. Integrity Alliance LLC. purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth about $230,000. Focus Partners Wealth increased its position in shares of Edwards Lifesciences by 6.1% during the 1st quarter. Focus Partners Wealth now owns 67,271 shares of the medical research company’s stock valued at $4,876,000 after purchasing an additional 3,891 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its position in shares of Edwards Lifesciences by 7.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 7,463 shares of the medical research company’s stock valued at $541,000 after purchasing an additional 503 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on EW. Evercore ISI reaffirmed an “outperform” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Monday. Stifel Nicolaus boosted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 price objective (up previously from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $90.00 to $97.00 in a research report on Friday. Finally, Wells Fargo & Company set a $100.00 price target on shares of Edwards Lifesciences in a research note on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,885,571.40. This trade represents a 4.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total value of $971,384.40. Following the transaction, the vice president directly owned 31,870 shares in the company, valued at $2,729,984.20. This trade represents a 26.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 57,824 shares of company stock valued at $4,863,323 over the last ninety days. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Up 0.7%

Shares of NYSE EW opened at $85.14 on Friday. The firm’s fifty day moving average is $85.06 and its 200 day moving average is $80.32. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The company has a market cap of $49.41 billion, a price-to-earnings ratio of 36.70, a PEG ratio of 3.44 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the firm earned $0.67 EPS. The company’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.